For New Antipsychotic Users, Dose, Duration Impact Mortality

This article originally appeared here.
Share this content:
For New Antipsychotic Users, Dose, Duration Impact Mortality
For New Antipsychotic Users, Dose, Duration Impact Mortality

TUESDAY, May 17, 2016 (HealthDay News) -- Dose and duration of therapy are associated with mortality for new antipsychotic users, according to a study published online May 10 in the Journal of the American Geriatrics Society.

Linda Simoni-Wastila, Ph.D., from the University of Maryland in Baltimore, and colleagues conducted a retrospective cohort study of Medicare beneficiaries who had a Minimum Data Set 2.0 clinical assessment completed between 2007 and 2009. The authors identified three mutually exclusive cohorts of new antipsychotic users with evidence of severe mental illness (SMI; 5,621 participants); dementia with behavioral symptoms (dementia + behavior) without SMI (1,090 participants); or delirium without SMI or dementia + behavior (2,100 participants). The dose (modified standardized daily dose [mSDD]) and duration of therapy with antipsychotic were assessed monthly.

The researchers found that mortality risk was significantly lower for new antipsychotic users with a mSDD of ≤1 versus those with a mSDD >1 (hazard ratio [HR]SMI, 0.77; HRdementia + behavior, 0.52; and HRdelirium, 0.61, respectively). Significantly lower mortality was seen with longer duration of antipsychotic use (91 to 184 days for SMI and delirium) versus short duration of use (≤30 days for SMI; ≤7 days for delirium). In the SMI cohort, the interaction between dose and duration was statistically significant (P < 0.001).

"Prescribers should monitor antipsychotic dosage throughout the course of antipsychotic treatment and customize dose and duration regimens to an individual's indications," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »